Literature DB >> 27422379

Clinical measures in transthyretin familial amyloid polyneuropathy.

Teresa Coelho1, Aaron Vinik2, Etta J Vinik2, Tara Tripp3, Jeff Packman4, Donna R Grogan4.   

Abstract

INTRODUCTION: This observational, cross-sectional, single-center study aimed to identify instruments capable of measuring disease progression in transthyretin familial amyloid polyneuropathy (TTR-FAP).
METHODS: The relationship between disease stage and Neuropathy Impairment Score-Lower Limbs (NIS-LL) and Norfolk Quality of Life-Diabetic Neuropathy (Norfolk QOL-DN) total score was assessed in 61 (stages 1-3) patients with TTR-FAP (V30M variant) and 16 healthy controls. Composite measures of large- and small-nerve fiber function, and modified body mass index (mBMI) were also assessed.
RESULTS: Ordinal-based NIS-LL and Norfolk QOL-DN scores discriminated between disease stages (P < 0.0001 for NIS-LL and Norfolk QOL-DN). Longer disease duration correlated with worse NIS-LL and Norfolk QOL-DN. Karnofsky performance score declined progressively by disease stage. Composite measures of nerve fiber function differentiated stage 1 from stage 2 disease. The mBMI declined with advancing disease.
CONCLUSIONS: NIS-LL, Norfolk QOL-DN score, composite endpoints of nerve fiber function, and mBMI are valid, reliable measures of TTR-FAP severity. Muscle Nerve 55: 323-332, 2017.
© 2016 Wiley Periodicals, Inc.

Entities:  

Keywords:  Neuropathy Impairment Score; Norfolk Quality of Life; amyloidosis; modified body mass index; nerve fiber function

Mesh:

Year:  2016        PMID: 27422379     DOI: 10.1002/mus.25257

Source DB:  PubMed          Journal:  Muscle Nerve        ISSN: 0148-639X            Impact factor:   3.217


  25 in total

Review 1.  Autonomic involvement in hereditary transthyretin amyloidosis (hATTR amyloidosis).

Authors:  Alejandra Gonzalez-Duarte
Journal:  Clin Auton Res       Date:  2018-03-06       Impact factor: 4.435

2.  Predictive model of response to tafamidis in hereditary ATTR polyneuropathy.

Authors:  Cecília Monteiro; Jaleh S Mesgazardeh; João Anselmo; Joana Fernandes; Marta Novais; Carla Rodrigues; Gabriel J Brighty; David L Powers; Evan T Powers; Teresa Coelho; Jeffery W Kelly
Journal:  JCI Insight       Date:  2019-06-20

Review 3.  Transthyretin familial amyloid polyneuropathy: an update.

Authors:  Violaine Plante-Bordeneuve
Journal:  J Neurol       Date:  2017-12-16       Impact factor: 4.849

4.  ATTR amyloidosis during the COVID-19 pandemic: insights from a global medical roundtable.

Authors:  Thomas H Brannagan; Michaela Auer-Grumbach; John L Berk; Chiara Briani; Vera Bril; Teresa Coelho; Thibaud Damy; Angela Dispenzieri; Brian M Drachman; Nowell Fine; Hanna K Gaggin; Morie Gertz; Julian D Gillmore; Esther Gonzalez; Mazen Hanna; David R Hurwitz; Sami L Khella; Mathew S Maurer; Jose Nativi-Nicolau; Kemi Olugemo; Luis F Quintana; Andrew M Rosen; Hartmut H Schmidt; Jacqueline Shehata; Marcia Waddington-Cruz; Carol Whelan; Frederick L Ruberg
Journal:  Orphanet J Rare Dis       Date:  2021-05-06       Impact factor: 4.123

5.  Pharmacological treatment for familial amyloid polyneuropathy.

Authors:  Francesca Magrinelli; Gian Maria Fabrizi; Lucio Santoro; Fiore Manganelli; Giampietro Zanette; Tiziana Cavallaro; Stefano Tamburin
Journal:  Cochrane Database Syst Rev       Date:  2020-04-20

Review 6.  Expert consensus recommendations to improve diagnosis of ATTR amyloidosis with polyneuropathy.

Authors:  David Adams; Yukio Ando; João Melo Beirão; Teresa Coelho; Morie A Gertz; Julian D Gillmore; Philip N Hawkins; Isabelle Lousada; Ole B Suhr; Giampaolo Merlini
Journal:  J Neurol       Date:  2020-01-06       Impact factor: 4.849

7.  Trial design and rationale for APOLLO, a Phase 3, placebo-controlled study of patisiran in patients with hereditary ATTR amyloidosis with polyneuropathy.

Authors:  David Adams; Ole B Suhr; Peter J Dyck; William J Litchy; Raina G Leahy; Jihong Chen; Jared Gollob; Teresa Coelho
Journal:  BMC Neurol       Date:  2017-09-11       Impact factor: 2.474

8.  Phenotypic expressions of hereditary Transthyretin Ala97Ser related Amyloidosis (ATTR) in Taiwanese.

Authors:  Hui-Ching Hsu; Ming-Feng Liao; Jung-Lung Hsu; Ai-Lun Lo; Hung-Chou Kuo; Rong-Kuo Lyu; Victor Chien-Chia Wu; Chih-Wei Wang; Long-Sun Ro
Journal:  BMC Neurol       Date:  2017-09-07       Impact factor: 2.474

9.  Tafamidis delays neurological progression comparably across Val30Met and non-Val30Met genotypes in transthyretin familial amyloid polyneuropathy.

Authors:  B K Gundapaneni; M B Sultan; D J Keohane; J H Schwartz
Journal:  Eur J Neurol       Date:  2017-12-26       Impact factor: 6.089

10.  Positive Effectiveness of Tafamidis in Delaying Disease Progression in Transthyretin Familial Amyloid Polyneuropathy up to 2 Years: An Analysis from the Transthyretin Amyloidosis Outcomes Survey (THAOS).

Authors:  Rajiv Mundayat; Michelle Stewart; Jose Alvir; Sarah Short; Moh-Lim Ong; Denis Keohane; Denise Rill; Marla B Sultan
Journal:  Neurol Ther       Date:  2018-04-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.